Inari Medical, Inc. (NASDAQ:NARI - Get Free Report) CEO Andrew Hykes sold 3,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $55.29, for a total transaction of $165,870.00. Following the sale, the chief executive officer now owns 439,310 shares in the company, valued at approximately $24,289,449.90. The trade was a 0.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Andrew Hykes also recently made the following trade(s):
NARI traded up $1.04 during trading on Friday, hitting $55.45. The company's stock had a trading volume of 1,874,948 shares, compared to its average volume of 998,000. The business's 50 day simple moving average is $49.84 and its 200-day simple moving average is $48.13. The firm has a market cap of $3.25 billion, a PE ratio of -41.07 and a beta of 0.97. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $66.61.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Vestal Point Capital LP lifted its position in Inari Medical by 342.9% during the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock valued at $63,922,000 after purchasing an additional 1,200,000 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Inari Medical by 113.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company's stock valued at $71,324,000 after buying an additional 786,691 shares in the last quarter. Armistice Capital LLC grew its stake in shares of Inari Medical by 353.1% during the 2nd quarter. Armistice Capital LLC now owns 1,009,252 shares of the company's stock valued at $48,595,000 after acquiring an additional 786,501 shares during the period. Jennison Associates LLC increased its holdings in Inari Medical by 63.2% in the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company's stock worth $65,021,000 after acquiring an additional 610,468 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Inari Medical by 101.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company's stock worth $32,790,000 after acquiring an additional 400,198 shares during the period. 90.98% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have recently weighed in on NARI. Truist Financial boosted their price target on Inari Medical from $50.00 to $63.00 and gave the stock a "hold" rating in a research note on Wednesday. Leerink Partnrs raised Inari Medical to a "hold" rating in a research report on Tuesday, September 3rd. Oppenheimer began coverage on shares of Inari Medical in a report on Tuesday. They set an "outperform" rating and a $75.00 price target on the stock. Robert W. Baird lifted their price target on shares of Inari Medical from $66.00 to $67.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 29th. Finally, Needham & Company LLC restated a "hold" rating on shares of Inari Medical in a research report on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Inari Medical currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.80.
Get Our Latest Stock Report on Inari Medical
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Inari Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inari Medical wasn't on the list.
While Inari Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.